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Summary
Systemic-onset juvenile idiopathic arthritis (SoJIA), some-
times called Still’s disease, is a systemic inflammatory dis-
ease classified within the spectrum of juvenile idiopathic
arthritis (JIA). It is an orphan disease with often a chronic
course and a major impact on the affected children and
their families. This disorder is unique in terms of clinical
manifestations, prognosis and response to conventional im-
munosuppressants. The objectives of this review are to de-
scribe SoJIA and emphasise the recent advances in the
pathogenesis and treatment, which have transformed the
care and the prognosis of this potentially life-threatening
paediatric condition.
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Historical view on Still’s disease and
SoJIA
In 1897, while working as a registrar at the Hospital for
Sick Children at Great Ormond Street in London, Sir Ge-
orge Frederick Still described a series of patients with three
patterns of childhood arthritis, one of which came to be
known later as Still’s disease, corresponding to what we
today call SoJIA [1]. Some authors still refer to this disease
entity as Still’s disease, although the international termin-
ology of JIA has been accepted worldwide. Of note,
Diamand-Berger had already described the disease in his
medical thesis in 1891, six years before Sir G.F. Still. Since
chronic arthritis in children and adolescents is clearly a het-
erogeneous condition, it became evident that classification
criteria were mandatory to define homogeneous categor-
ies of patients for clinical research. Since 1995, a group
of experts under the patronage of the International League
against Rheumatism proposed a classification based on an
international consensus. Seven subtypes of JIA were
defined, and this replaced the previous categories of juven-
ile chronic arthritis (JCA) and juvenile rheumatoid arthritis
(JRA) [2].
JIA is one of the most common paediatric chronic illnesses:
the prevalence rate varies widely in the different series
(between 10 and 400 cases/100,000), and the yearly in-
cidence varies between 2 and 19.5 cases for 100,000 chil-
dren [3]. SoJIA as a subtype includes about 10–15% of
all JIA patients, but the percentage is higher when severe
JIA cases are considered [4, 5]. At onset, it is clinically
well distinguished from other forms of JIA by the prom-
inence of extra-articular features such as spiking fevers, a
salmon-coloured skin rash, lymphadenopathy and serosit-
is [6]. However, diagnosis is often challenging, since the
disease can mimic infections and malignancies. Unlike the
other forms of JIA, the affected child looks very ill, es-
pecially during fever spikes, and may present with a life-
threatening complication known as macrophage activation
syndrome (MAS).
SoJIA patients are classically treated first with non-ster-
oidal anti-inflammatory drugs, and if the inflammation is
not controlled, high dose corticosteroids are used. Before
the use of biotherapies, the disease was difficult to control
in a significant number of patients and long lasting steroid
treatment induced severe side effects, mainly growth fail-
ure and osteoporosis. The clinical course at later stages of
SoJIA is highly variable, with about a third of cases having
a monocyclic course, a third having a relapsing-remitting
course, and another third having continuous disease activ-
ity. Systemic features tend to subside over time, while pro-
gressive and destructive arthritis can develop [5].
A case report of SoJIA with severe
presentation
A 30-month-old healthy girl presented with a 3 week his-
tory of daily spiking fevers, fatigue, weight loss and poor
general conditions. She refused to walk and wanted to be
carried by her parents. The presence of hand and feet swell-
ing led to an admission to the emergency room. On ex-
amination, she was febrile at 38.6 °C, with an ill appear-
ance, and irritable. General examination was normal except
for a discrete erythematous rash on the trunk and the ex-
tremities, and enlarged cervical lymph nodes. On muscu-
loskeletal examination, almost all joints from the cervical
spine to the toes were involved, with swelling, tender-
ness, pain and reduced mobility. The patient’s laboratory
tests showed major systemic inflammation with anaemia,
neutrophilia, thrombocytosis and hyperferritinaemia. Liver
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enzymes were normal; total IgG levels were increased,
and autoantibodies were all negative. An echocardiography
showed a moderate pericardial effusion and could exclude
coronary involvement. Infection and neoplasia were ex-
cluded by laboratory tests and radiological examinations.
Based on the clinical presentation and after exclusion of
other causes, we could confirm the diagnosis of SoJIA. The
patient was treated with high doses of steroids (intravenous
followed by oral) and indomethacin. She showed a transi-
ent clinical improvement (absence of fever and rash), but
persistence of polyarthritis and laboratory inflammation.
Methotrexate subcutaneously was added without any ef-
fect on joint inflammation. Tocilizumab (anti-IL-6 recept-
or antibody) was therefore introduced with infusions every
2 weeks. During the following weeks, both systemic and
joint inflammation improved significantly and the steroid
dose could be decreased. The patient could walk and play
again, but many joints remained inflamed, in particular the
knees and wrists which were injected with corticosteroids.
One year after diagnosis, the patient was treated with tocil-
izumab, methotrexate and prednisone (0.5 mg/kg/d), labor-
atory tests were within the normal range, but 27 joints still
showed signs of inflammation. We then tried to change the
treatment from tocilizumab to etanercept for a better con-
trol of joint inflammation. This did not allow a better con-
trol of joint inflammation, and the inflammatory markers
rose again leading to a new change of the biotherapy to to-
cilizumab again. We present here a case with a particularly
severe course of SoJIA, which significantly improved with
a newly recognised treatment for this disease. As illustrated
by this case, the course of illness had a major impact on the
quality of life for the patient and her family. In complement
to the medical care, the family had access to a hotline for
counselling and support from our nursing team, who also
provided help for the injections. This support was useful to
achieve a good therapeutic compliance and provide the ne-
cessary service from the network.
Clinical presentation and differential
diagnosis
The diagnosis of SoJIA should be considered in children
or adolescents with typical spiking fevers associated with
arthritis or polyarthralgia. This is often a challenging dia-
gnosis since many other causes for the fever need to be ex-
cluded. SoJIA may present at any age and there is no clear
gender predominance. A seasonal variation for disease on-
set was suspected, but not confirmed in large studies. The
typical picture of SoJIA presents with a very ill child, who
is febrile, anaemic and in pain [5–7]. Figure 1 illustrates
some of the most important features and complications of
the disease.
Any joint may be affected at disease onset, and involve-
ment may be oligo- or polyarticular, but arthritis tends to
increase in severity over time. In about a third of the pa-
tients, only arthralgia are reported at the onset of disease,
and the presence of clear arthritis may be observed even
years after the occurrence of systemic symptoms [4]. The
typical spiking fever goes up to 39° or 40° once or twice
daily and returns rapidly to 37° or below [6]. A persistent
fever over 24 hours should suggest other diagnoses, or
MAS complicating SoJIA [8]. An erythematous macular
rash (salmon-pink coloured) often accompanies the fever;
it is usually localised over the trunk and the proximal ex-
tremities, tends to be migratory, and may be urticarial or
sometimes pruritic [9, 10]. Enlargement of the lymph
nodes, the liver and/or the spleen may occur. In less than
10% of the patients a pericarditis will develop, often
asymptomatic and only rarely inducing a tamponade [4,
11]. The two major complications of SoJIA are MAS and
secondary amyloidosis [12]. MAS is a severe, potentially
Figure 1
(1a) Typical temperature curve with one fever peak per day; (1b)
short stature in a boy with SoJIA, beginning of disease at 2.5 years;
(1c) rash in SoJIA.
Figure 2
Hip replacement in a patient with SoJIA.
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life-threatening complication characterised by the excess-
ive activation of well-differentiated macrophages, resulting
in persistent fever with generalised malaise, hepatosplen-
omegaly, lymphadenopathy, liver failure, intravascular co-
agulation, and neurological involvement. Laboratory tests
show a decrease of the inflammatory parameters and a re-
lative hypofibrinogenemia (often normal, rather than elev-
ated levels due to systemic inflammation), elevated liver
enzymes, hemocytopenia, high ferritin levels and increased
serum triglycerides [13, 14]. This complication, resembling
reactive hemophagocytic lymphohistiocytosis, can be life-
threatening and needs to be quickly recognised and treated
to avoid a fatal outcome. The diagnosis of MAS associated
with active SoJIA may be difficult: specific diagnostic
guidelines have been developed to help the physician [13].
Secondary amyloidosis is observed in patients with
treatment-resistant disease evolving over many years and
can lead to renal insufficiency due to parenchymal de-
position of serum amyloid A [15]. This rare complication
should not be seen anymore in the future due to a better
control of systemic inflammation with the new biological
therapies. Other complications include a destructive pol-
yarthritis (fig. 2) and growth retardation which is related to
the disease activity and, in some patients, a prolonged cor-
ticosteroid therapy.
The diagnosis of SoJIA is based on internationally recog-
nised classification criteria (table 1) [2]. Since the presence
of arthritis is mandatory, the diagnosis can only be sus-
pected at disease onset in patients without arthritis. JIA is
defined by the presence of arthritis for at least 6 weeks
with an onset before 16 years of age, after exclusion of
all other causes. According to these classification criteria,
four different conditions, listed in table 1, will exclude
SoJIA. These exclusion criteria are controversial in partic-
ular those considering the family history of the patient; in-
deed, a patient may develop SoJIA even if a close relative
is affected by a different disease such as psoriasis or spon-
dylarthritis. Although SoJIA is considered as part of JIA,
it is a disease distinct from the other forms: different clin-
ical presentation, pathophysiology and response to treat-
ment. The oligoarticular and polyarticular forms of JIA
are considered as autoimmune diseases and often present
with autoantibodies (antinuclear antibodies or rheumatoid
factor). However, SoJIA is closer to the group of autoin-
flammatory diseases and the detection of positive
autoantibodies is uncommon [16–18]. Adult-onset Still’s
disease is an entity similar to SoJIA occurring in adults.
Different sets of criteria are used for diagnosis and the most
commonly used are the criteria of Yamaguchi [19]. The
presence of clear arthritis is not mandatory in contrast to
the childhood classification, allowing the inclusion of all
cases affected by the disease. We believe that the criteria
for SoJIA should be adapted in order to integrate the recent
findings suggesting the affiliation to the group of autoin-
flammatory diseases and to standardise the classification
for both the paediatric and the adult form of this condition.
The main diagnostic challenge for SoJIA is the absence of
a pathognomonic clinical feature or laboratory marker. In
consequence, the clinician has to consider a wide differ-
ential diagnosis (see table 2) and perform a large number
of investigations to exclude such alternative possibilities.
Laboratory and radiological work-up will depend on dis-
ease presentation: an atypical clinical picture and in par-
ticular the lack of clear arthritis will lead to broader in-
vestigations. Many different infections will be considered,
such as occult bacterial infection, brucellosis, Lyme dis-
ease, cat scratch disease, tuberculosis, infectious mononuc-
leosis. Malignancies, for example leukaemia, lymphoma
and neuroblastoma, may mimic the symptoms of SoJIA,
and need to be excluded, if they are clinically suspected,
with a bone marrow aspirate. Fever and arthritis may also
suggest other inflammatory diseases, like systemic lupus
erythematosus, systemic vasculitis, Kawasaki disease, Be-
hçet disease and inflammatory bowel disease. Acute
rheumatic fever (ARF) is a more common differential dia-
gnosis in developing countries and will follow a strepto-
coccal A infection; the pattern of arthritis is however acute
and migratory and the episode is self-limiting. Recurrent
fever syndromes can sometimes present with osteoarticular
involvement associated with fever, but the pattern of fever,
the clinical picture and the family history will help to dis-
tinguish them from SoJIA.
Laboratory investigations will first evaluate the level of in-
flammation. Levels of erythrocyte sedimentation rate and
C-reactive protein are usually very high. A complete blood
count is mandatory to exclude lymphoproliferative dis-
eases; it will typically show an inflammatory anaemia, a
leukocytosis with neutrophil predominance and a thrombo-
cytosis. A protein produced by neutrophils, myeloid react-
ive proteins (MRP), is present at very high serum levels in
SoJIA, much higher than in other inflammatory illnesses
[20]. In the future, this new laboratory test may help to
distinguish SoJIA from other febrile conditions. Ferritin is
often increased, but very high serum levels will suggest
MAS. The immunological status is typically characterised
by the absence of autoantibodies.
Table 1: Classification criteria for SoJIA.
Arthritis with or preceding daily fever with a duration of at least 2 weeks accompanied by at least 1 of the following symptoms during the first 6 months.
– Erythematous rash;
– Lymphadenopathy;
– Hepatomegaly and/or splenomegaly;
– Serositis.
Exclusion criteria
– Psoriasis or history of psoriasis in the patient or first degree relative;
– Arthritis in a boy (6 year-old or more) positive for HLA-B27;
– Ankylosing spondylitis, enthesitis with arthritis, sacro-ileitis and inflammatory bowel disease, Reiter syndrome or acute anterior uveitis in a first degree relative;
– Presence of rheumatoid factor type IgM confirmed in an interval of at least 3 months apart.
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News on pathogenesis: is it an
autoimmune or an auto-inflammatory
disease?
It is now becoming increasingly clear that the markedly
distinct clinical presentation of the systemic form of JIA is
associated with unique immunologic abnormalities. Sever-
al lines of evidence suggest that the role of the adaptive
immune system in SoJIA may be rather limited compared
to the other JIA types, while the contribution of the innate
immunity may be much more prominent [16, 21]. The
development of classic autoimmunity is typically associ-
ated with the presence of autoreactive antigen-specific T
lymphocytes (due to failure of self-tolerance mechanisms),
high-titer autoantibodies, and strong MHC class II associ-
ations. On the contrary, auto-inflammatory disorders (for
example Familial Mediterranean Fever) show abnormalit-
ies in innate immunity pathways, lack MHC associations
and autoantibodies or antigen specific T cells. Predomin-
ance of monocytes and neutrophils rather than lymphocytes
as effector cells is another important feature of these dis-
eases. Abnormalities in the innate immunity play a major
role in the pathogenesis of SoJIA, which should be viewed
as an auto-inflammatory rather than a classic autoimmune
disease. Indeed, many features of SoJIA are similar to
those seen in auto-inflammatory syndromes, for example
presence of fever, multisystem involvement, absence of
autoantibodies, and a lack of MHC Class II associations
(unlike other forms of JIA). However, a subset of patients
with SoJIA may develop autoimmune features in the long-
term, such as ANCA-associated glomerulonephritis [22].
The cytokines critical to the perpetuation of the inflammat-
ory process in the systemic form of JIA also appear to be
different from those in other JIA categories. Clinical and
translational studies suggest the pivotal role for two potent
pro-inflammatory cytokines: Interleukin-1 (IL-1) and In-
terleukin -6 (IL-6) [18]. Indeed, in SoJIA, aberrant activa-
tion of phagocytes leads to the secretion of pro-inflammat-
ory cytokines such as IL-1, IL-6 and IL-18, in addition to
other inflammatory proteins such as S100A8, S100A9 and
S100A12 [17, 20, 23–27].
Although the source of excess IL-1 in this disorder is still
obscure, elegant studies from Virginia Pascual’s group in
Dallas have shown a major role of this cytokine [18], and
response to IL-1 inhibition has been demonstrated in sev-
eral studies including a recent multicenter French trial
(whereas anti-TNF therapy offers only limited benefit in
SoJIA patients) [28–31]. Of note, compelling evidence for
the involvement of IL-1 in this disorder comes from the ef-
ficacy of IL-1 blockage with Anakinra in clinical trials.
The group from Dallas has developed two complementary
approaches using microarray technology: (a) analysis of
transcriptional patterns in patients’ peripheral blood mono-
nuclear cells; and (b) analysis of the transcriptional
changes induced by adding serum from active patients to
healthy peripheral blood mononuclear cells (PBMCs). Ser-
um from SoJIA patients induced transcription of various
innate immunity genes, including IL-1β, in PBMCs ob-
tained from healthy individuals. Moreover, the authors ana-
lysed leukocyte gene expression profiles of paediatric
SoJIA patients and compared them to healthy controls and
to subjects with other febrile illnesses. Genes differentially
expressed in SoJIA patients compared with healthy chil-
dren were identified, including 12 genes which accurately
classified an independent set of SoJIA patients with sys-
temic disease. Transcripts that changed significantly in pa-
tients undergoing IL-1 blockade were also identified. Thus,
according to these studies, signatures can be used to distin-
guish SoJIA from other febrile illnesses and to assess re-
sponse to anti-cytokine therapy [32].
The aforementioned French study [31] was a double blind,
placebo-controlled trial conducted on patients with severe,
persistently active disease. Its aim was to evaluate the effic-
acy and safety of Anakinra, as well as to assess treatment
effect on surrogate markers of SoJIA activity and gene ex-
pression profile. The primary objective was to compare the
efficacy of a one-month treatment with Anakinra (2 mg/
kg subcutaneously daily, maximum 100 mg) to a placebo
between 2 groups of 12 patients each. Response was
defined by a 30% improvement of paediatric ACR core-
set criteria for JIA, in addition to resolution of fever and
systemic symptoms, and a decrease of at least 50% of
Table 2: Differential diagnosis of SoJIA.
Patients <5 years
– Bacterial infections;
– Malaria;
– Leukemia;
– Neuroblastoma;
– Viral infections;
– Kawasaki syndrome;
– Hereditary recurrent fever syndromes or other auto-inflammatory syndromes with beginning in early childhood;
– Blau syndrome;
– Sweet syndrome;
– PFAPA (periodic fever, adenopathy, pharyngitis, aphtosis).
Patient >5 years
– All the above mentioned;
– Takayasu syndrome;
– Connective tissue diseases;
– Rheumatic fever;
– Familial Mediterranean Fever or other periodic fever syndromes (TRAPS);
– Behçet disease;
– Polyarteritis nodosa;
– Castleman syndrome;
– Inflammatory bowel disease.
Review article: Current opinion Swiss Med Wkly. 2012;142:w13582
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 9
both C-reactive protein and erythrocyte sedimentation rate.
Secondary objectives included tolerance and efficacy as-
sessment over 12 months, pharmacokinetic analyses, treat-
ment effect on blood gene expression, anti-pneumococcal
response, serum amyloid A and ferritin levels, and per-
centage of glycosylated ferritin. At one month, there was
a significant difference in the response rate between pa-
tients treated with Anakinra and placebo. The number of
adverse events, mainly pain related to injections, was sim-
ilar between both groups. Ten patients from the placebo
group switched to Anakinra at Month 1 and nine were re-
sponders at Month 2. Blood gene expression profiling ana-
lyses showed a SoJIA signature at inclusion that rapidly
wore off upon initiation of Anakinra treatment, allowing
to distinguish patients treated with Anakinra from patients
treated with placebo. Despite being a relatively small study,
this represents the first placebo-controlled trial of Anakinra
in SoJIA; results should be confirmed in larger scale stud-
ies. Of interest, an up-regulation of type I IFN-regulated
transcripts, which is not a feature of untreated SoJIA, was
induced in the majority of Anakinra-treated patients. The
molecular and cellular basis for an IL-1 β/type I IFN cross-
regulation in SoJIA remains unknown, although it is known
that type I IFN decreases IL-1β and induces IL-1Ra pro-
duction by PBMCs in vitro. A similar cross-regulation has
been described for type I IFN and TNF (patients with
rheumatoid arthritis and Crohn’s disease treated with TNF
antagonists develop anti-nuclear Abs and some of them
display symptoms of systemic lupus erythematosus, a type
I IFN-mediated disease). Whether the upregulation of type
I IFN-inducible genes in Anakinra-treated patients could
have clinical consequences through the triggering of adapt-
ive immunity remains to be determined.
However, results have not been uniformly positive; it
seems that there are two different populations with regard
to IL-1 response [33], and moreover, the seemingly re-
duced success of IL-1 inhibition in subjects with long-
standing disease suggests that later in the pathological pro-
cess other mechanisms might be involved.
The role of another important cytokine, Interleukin-6
(IL-6), had been proposed by De Benedetti and colleagues
in the past [24, 25]. IL-6 is markedly elevated in both peri-
pheral blood and synovial fluid of patients with SoJIA, and
the levels of IL-6 expression appear to correlate with the
overall clinical activity of the disease and with distinct-
ive clinical features such as thrombocytosis, microcytic
anaemia, growth retardation and osteopenia. Furthermore,
studies of the unique quotidian fever pattern of system-
ic JIA show that IL-6 concentrations rise and fall in con-
cert with the temperature spikes [34]. Tocilizumab is a
humanised anti-human interleukin-6 (IL-6) receptor mono-
clonal antibody of the IgG1 subclass produced by recom-
binant DNA technology that inhibits the function of IL-6.
Clinical studies with tocilizumab have been successful in
SoJIA, with one placebo-controlled Japanese trial already
published [35] and an international phase III study already
completed.
In these cases therapeutic experience has taught us a lot
about disease pathogenesis and the importance of these two
cytokines has been confirmed by proving the clinical effic-
acy of blocking their activity. This effect does not seem to
be as important in other types of JIA.
IL-18, originally described as an IFN-γ inducing factor
mainly produced by activated macrophage lineage cells,
stimulates a variety of inflammatory responses. Serum
levels of IL-18 have been found to be elevated in patients
with SoJIA [26, 36–38] even during inactive disease phases
when concentrations of other cytokines normalised [39].
Moreover, it has been shown that the mechanism of the im-
paired NK cell function that is present in SoJIA involves a
defect in the IL-18 receptor beta-phosphorylation [40].
With regard to the calcium-binding proteins of the S100
family, they are known to be secreted specifically by ac-
tivated phagocytes including monocytes, macrophages and
neutrophils. These proteins (S100A8, A9, and A12) are
also known as myeloid-related proteins (MRPs). In SoJIA,
high circulating levels of these molecules are found, much
more than in other inflammatory conditions including dif-
ferent forms of arthritis; hopefully they might also be use-
ful as biomarkers for prognosis [20].
New treatments
The recent insights into the pathophysiological mechan-
isms in SoJIA have led to major changes in the man-
agement of this disease. Until recently, the treatment al-
gorithms in SoJIA included mainly corticosteroids and me-
thotrexate. Since their introduction, TNF-inhibitors have
also been frequently used in these patients [41–43].
Thalidomide [44] and even autologous stem cell transplant-
ation have been used in patients with particularly severe
disease. However, methotrexate and anti-TNF [45] seem to
be less effective for SoJIA than for other JIA categories.
With advancing knowledge on disease pathogenesis, two
cytokines have been the target of modern biologic treat-
ment of SoJIA, and clinical experience has now shown us
that biologics blocking IL-1 and IL-6 are very effective.
The most relevant experiences with the use of anakinra
have already been summarised in the previous paragraph;
other reports have followed and confirmed its efficacy. A
recent multicenter paper has also suggested that, if given
as a first-line drug, anakinra leads to rapid resolution of
systemic symptoms and arthritis [46]; however the retro-
spective nature of this study and the lack of a control group
make it difficult to draw firm conclusions. Canakinumab,
a fully human anti-interleukin-1β (anti-IL-1β) monoclonal
antibody, is another new IL-1 inhibiting agent currently
studied in SoJIA in the USA and Europe. Results of a phase
II study have just been published [47], while those of a
phase III trial should be available soon. Rilonacept (or IL-1
Trap) is a fusion protein consisting of the two human IL1
receptor extracellular domains and the Fc portion of human
IgG1. It incorporates the extracellular domains of both re-
ceptor chains required for IL-1 signalling within a single
molecule: the IL-1 type I receptor and the IL-1 receptor ac-
cessory protein. Due to this, the IL-1 Trap molecule might
be a more efficient inhibitor of in vivo IL-1 signalling than
anakinra. Recently, Rilonacept has been proven to be ef-
fective in familial cold auto-inflammatory syndromes [48],
and a phase III trial in SoJIA is in progress.
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The anti-IL-6 receptor antibody (Tocilizumab) has been
studied in several trials, and the drug is now approved in
the U.S. and Europe for the treatment of active SoJIA [35,
49].
The optimal treatment for resistant cases has to be tailored
to individual patients; in case of failure of NSAIDs and a
short course of corticosteroids ± methotrexate (or in case
of corticodependance) referral to a specialised paediatric
rheumatology centre is recommended. Although the Amer-
ican College of Rheumatology has released treatment re-
commendations [50], and a consensus conference by mem-
bers of the Childhood Arthritis & Rheumatology Research
Alliance has also been published recently [51], head-to-
head trials are not available and therefore comparing the ef-
ficacy of different biologics is difficult. Hence, the decision
of which biologic therapy to administer in a specific situ-
ation cannot be made by using standardised protocols.
Table 3 summarises the different treatment used for SoJIA.
Conclusions and perspective
SoJIA is a severe disorder, most likely belonging to the
group of auto-inflammatory diseases. Recently, it has been
shown that cytokines play a major role in its pathogenesis,
and that blocking these molecules may allow a good con-
trol of systemic and joint inflammation. These drugs have
transformed the prognosis of SoJIA patients by preventing
the damage due to the inflammatory process and to side ef-
fects, in particular of the chronic use of high doses of cor-
ticosteroids. SoJIA remains a disease with a long course,
often over many years, and the risk of complications due
to the illness or the medications is still significant. Conse-
quently, patients with SoJIA need to be cared for by a spe-
cialised medical team, used to this condition and to biother-
apies. Additionally, the impact on the quality of life of the
child and the family is major, and will require the support
of a multidisciplinary team, including nurses and physic-
al therapists. The recent progresses in the understanding of
SoJIA have changed the life of this orphan disease and for
our patients. However, SoJIA still represents a significant
burden and will require our future efforts in research and
clinical care to further improve the daily life and the out-
come of our young patients.
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Figures (large format)
Figure 1
(1a) Typical temperature curve with one fever peak per day; (1b) short stature in a boy with SoJIA, beginning of disease at 2.5 years; (1c) rash
in SoJIA.
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Figure 2
Hip replacement in a patient with SoJIA.
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